Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2/CD70 Bi-specific CAR-T Cells for Cancer Treatment
NCT05438368Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bi-4SCAR-GD2/CD70 T cells in cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Number of patients with adverse events at 6 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
bi-4SCAR-GD2/CD70 T cells
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05438368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438368.